SAN FRANCISCO, CA, USA I June 20, 2025 I Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.
“The amylin receptor is rapidly gaining clinical validation as a key target in obesity, driven by encouraging data from injectable peptide programs. We believe ACCG-2671 is well-positioned and differentiated as an oral small molecule frontrunner that is expected to enter clinical development by the end of 2025,” said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics. “The preclinical data being presented at ADA include the robust weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist underscoring ACCG-2671’s potential as a future small molecule backbone treatment for obesity. In addition, we will present data demonstrating the neuroprotective effects of GLP-1 receptor agonism in preclinical models of Parkinson’s disease, reinforcing the broad role of the GLP-1 receptor across different diseases.”
Presentation Details:
Title: Novel Oral Small Molecule ACCG-2671: A Dual Amylin and Calcitonin Receptor Agonist Development Candidate for Obesity Therapy
Poster #: 2184-LB
Session: Late Breaking Poster Session
Date: Sunday, June 22
Time: 12:30 p.m. – 1:30 p.m. CT
Summary: ACCG-2671 demonstrated high binding affinity and balanced potency in human calcitonin receptor (CTR) and amylin receptor (AMY3R) functional assays. In diet-induced obese rats, oral administration of ACCG-2671 resulted in significant, dose-dependent body weight reductions. Combination therapy with semaglutide (both as add-on and concurrent treatment) resulted in superior weight loss compared to monotherapy.
Title: Oral Small Molecule GLP-1 Receptor Agonist Demonstrates Beneficial Effects in Parkinson’s Disease–Like Model Using Humanized GLP-1R Mice
Poster #: 1985-LB
Session: Late Breaking Poster Session
Date: Sunday, June 22
Time: 12:30 p.m. – 1:30 p.m. CT
Summary: In a Parkinson’s disease mouse model, oral administration of GSBR-5595, a small molecule GLP-1 receptor agonist distinct from Structure Therapeutics’ clinical asset aleniglipron (GSBR-1290), significantly improved motor coordination and movement in both the rotarod and open field tests. Additionally, histopathological analyses revealed a significant increase in dopaminergic neurons. These findings suggest this GLP-1 receptor agonist showed neuroprotective effects by mitigating motor deficits and preserving dopaminergic neurons, highlighting a potential benefit in Parkinson’s disease.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
SOURCE: Structure Therapeutics
Post Views: 1,381
SAN FRANCISCO, CA, USA I June 20, 2025 I Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.
“The amylin receptor is rapidly gaining clinical validation as a key target in obesity, driven by encouraging data from injectable peptide programs. We believe ACCG-2671 is well-positioned and differentiated as an oral small molecule frontrunner that is expected to enter clinical development by the end of 2025,” said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics. “The preclinical data being presented at ADA include the robust weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist underscoring ACCG-2671’s potential as a future small molecule backbone treatment for obesity. In addition, we will present data demonstrating the neuroprotective effects of GLP-1 receptor agonism in preclinical models of Parkinson’s disease, reinforcing the broad role of the GLP-1 receptor across different diseases.”
Presentation Details:
Title: Novel Oral Small Molecule ACCG-2671: A Dual Amylin and Calcitonin Receptor Agonist Development Candidate for Obesity Therapy
Poster #: 2184-LB
Session: Late Breaking Poster Session
Date: Sunday, June 22
Time: 12:30 p.m. – 1:30 p.m. CT
Summary: ACCG-2671 demonstrated high binding affinity and balanced potency in human calcitonin receptor (CTR) and amylin receptor (AMY3R) functional assays. In diet-induced obese rats, oral administration of ACCG-2671 resulted in significant, dose-dependent body weight reductions. Combination therapy with semaglutide (both as add-on and concurrent treatment) resulted in superior weight loss compared to monotherapy.
Title: Oral Small Molecule GLP-1 Receptor Agonist Demonstrates Beneficial Effects in Parkinson’s Disease–Like Model Using Humanized GLP-1R Mice
Poster #: 1985-LB
Session: Late Breaking Poster Session
Date: Sunday, June 22
Time: 12:30 p.m. – 1:30 p.m. CT
Summary: In a Parkinson’s disease mouse model, oral administration of GSBR-5595, a small molecule GLP-1 receptor agonist distinct from Structure Therapeutics’ clinical asset aleniglipron (GSBR-1290), significantly improved motor coordination and movement in both the rotarod and open field tests. Additionally, histopathological analyses revealed a significant increase in dopaminergic neurons. These findings suggest this GLP-1 receptor agonist showed neuroprotective effects by mitigating motor deficits and preserving dopaminergic neurons, highlighting a potential benefit in Parkinson’s disease.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
SOURCE: Structure Therapeutics
Post Views: 1,381
